Trials / Completed
CompletedNCT05931380
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 238 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2023-07-31
- Primary completion
- 2025-06-19
- Completion
- 2025-06-19
- First posted
- 2023-07-05
- Last updated
- 2025-08-12
Locations
16 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05931380. Inclusion in this directory is not an endorsement.